Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Hold” by Analysts

Hologic, Inc. (NASDAQ:HOLX) has earned a consensus recommendation of “Hold” from the seventeen analysts that are currently covering the company, Marketbeat.com reports. Eleven research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $84.62.

A number of brokerages have recently commented on HOLX. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Citigroup cut their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HOLX. General Partner Inc. bought a new stake in Hologic in the 4th quarter worth $26,000. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the period. Finally, Smithfield Trust Co raised its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.7 %

Shares of HOLX stock opened at $61.77 on Tuesday. Hologic has a 52-week low of $60.34 and a 52-week high of $84.67. The business’s fifty day moving average is $65.08 and its 200 day moving average is $73.11. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market capitalization of $13.86 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.